Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in clinical trials focused on hypertrophic cardiomyopathy (HCM) and heart failure.</li><li>The launch of MYQORZO in the United States marked the company’s first approved therapy reaching patients, yielding net product revenues of $4.8 million during approximately nine weeks of commercial availability.</li><li>Early demand and healthcare provider (HCP) engagement exceeded internal expectations, supported by high prescriber awareness and favorable perceptions of MYQORZO’s clinical profile, including dosing flexibility, safety, and absence of drug-drug interaction requirements in the REMS (Risk Evaluation and Mitigation Strategy) program.</li></ul>

Cytokinetics reported developments in the first quarter of 2026 centered around the commercial launch of MYQORZO (aficamten) and progress in clinical trials focused on hypertrophic cardiomyopathy (HCM) and heart failure.The launch of MYQORZO in the United States marked the company’s first approved therapy reaching patients, yielding net product revenues of $4.8 million during approximately nine weeks of commercial availability.Early demand and healthcare provider (HCP) engagement exceeded internal expectations, supported by high prescriber awareness and favorable perceptions of MYQORZO’s clinical profile, including dosing flexibility, safety, and absence of drug-drug interaction requirements in the REMS (Risk Evaluation and Mitigation Strategy) program.

Cytokinetics' MYQORZO Launch: Can Early HCM Demand Define The Next Phase?

Cytokinetics Inc

Cytokinetics' MYQORZO Launch: Can Early HCM Demand Define The Next Phase?